Articles Archives - Page 70 of 725

MondayAug 26, 2024 10:30 am

ECGI Holdings Inc. (ECGI) Following Proven Path from High-End Equestrian Market to Full-Scope Luxury Market

Many renowned luxury brands – fashion houses and watchmakers – honor their equestrian roots and the strong relationship with horses, from Rolex and Longines to Burberry, Gucci, Hermès, and Ralph Lauren The companies, which have successfully remained in operation for decades and continue to be influenced by equestrian elements, underscore the proven potential of the luxury equestrian market to build large-scale luxury players Beyond an equestrian influence, leading fashion houses emphasize and embody quality, unmatched craftsmanship, and innovation, qualities that ECGI Holdings and its subsidiary Pacific Saddlery have adopted A diversified holding company, ECGI Holdings intends to cater to the…

MondayAug 26, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

The company has released key corporate and business updates and Q2 2024 financial results Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer's Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer's Disease, and INM-901-treated Alzheimer's Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

FridayAug 23, 2024 9:00 am

SenesTech Inc. (NASDAQ: SNES) Building Quickly Across Multiple Channels

SenesTech recently released Q2 2024 financial results and hosted a conference call, confirming 50% revenue growth in the just-ended quarter, and year-to-date growth 62% During the call, Joel Fruendt, President and CEO, discussed the company’s progress and accomplishments, including the successful efficacy trial of Evolve to support the product’s approval in certain states and international jurisdictions Fruendt also discussed the company’s commercialization plans, centered around the pivot from the reliance on direct sales to the use of distributors So far, SenesTech has onboarded three of the top five national multi-location distributors and is in the process of bringing the fourth…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

WednesdayAug 21, 2024 9:45 am

National Investment Banking Association 150th Investment Conference Comes to Ft. Lauderdale, Florida

The National Investment Banking Association (“NIBA”) invites the micro-cap and small-cap investment community to its 150th investment conference. The event will be held on September 4-5, 2024, at the Westin Fort Lauderdale Beach Resort, Ft. Lauderdale, Florida. Since 1982, The National Investment Banking Association has been a not-for-profit association for the micro-cap and small-cap investment community and has hosted 149 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry. NIBA’s member firms have a 40 year track record of successfully completing thousands of transactions totaling over $80 billion in new capital for emerging…

WednesdayAug 21, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q2 2024 Results

The company reported a 28% increase in revenue, a 6% rise in bookings, a 97% improvement in GAAP gross profit and a 444% increase in cash, for the second quarter of 2024, on a year over year basis D-Wave's CEO, Dr. Alan Baratz, summarized the company's ongoing strategic direction and provided an expansive list of achievements Highlights mentioned include a quantum AI product development roadmap extending D-Wave’s Leap(TM) quantum cloud service, an expanded partnership with Zapata AI, new customer hybrid quantum applications, and more D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first…

TuesdayAug 20, 2024 11:01 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs. “We are…

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

Site Search

Company Search

Category: Articles